Table 5.
Univariate analysis of the predictors of self-reported and confirmed antimicrobial use
| Variable | OR (95% CI) | p value |
|---|---|---|
| Age | 0.98 (0.96–1.02) | 0.43 |
| Gender, female | 2.30 (0.99–5.36) | 0.05 |
| Disease duration | 1.02 (0.97–1.07) | 0.53 |
| Number of ocrelizumab doses | 0.83 (0.64–1.08) | 0.16 |
| EDSS | 1.16 (0.96–1.39) | 0.12 |
| Prior immunosuppression | 1.77 (0.80–3.95) | 0.16 |
| Lymphocyte count | 1.51 (0.93–2.50) | 0.10 |
| Neutrophil count | 1.12 (0.94–1.34) | 0.22 |
| IgG level | 0.87 (0.72–1.06) | 0.16 |
| IgA level | 0.54 (0.28–1.05) | 0.07 |
| IgM level | 0.22 (0.04–1.10) | 0.07 |
| CD4+ | 1.15 (0.37–3.60) | 0.81 |
| CD8+ | 0.92 (0.12–6.99) | 0.94 |
| CD19+ | 0.09 (0.00–7824.67) | 0.68 |
CI confidence intervals, EDSS Expanded Disability Status Scale, OR odds ratio